Health ❯Healthcare ❯Pharmaceuticals ❯Drug Approval

Alzheimer's Disease

EU Regulators Reject Eli Lilly's Alzheimer's Drug Over Safety Concerns

The European Medicines Agency cites risks of brain swelling and bleeding, prompting Eli Lilly to seek re-examination of the decision.

EU Drug Agency Recommends Approval of First Alzheimer’s Treatment Targeting Disease Progression

EMA Approves Lecanemab for Early-Stage Alzheimer’s Treatment in EU

NHS Rejects Alzheimer’s Drug Donanemab Despite Promising Results

NHS Declines Coverage for Groundbreaking Alzheimer's Drug Due to High Costs